Bank of New York Mellon
CTNM

Bank of New York Mellon’s Contineum Therapeutics CTNM Stock Holding History

Bank of New York Mellon’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
+65,604
New +$860K ﹤0.01% 3316
2025
Q2 		– Sell
-19,899
Closed -$139K – 4295
2025
Q1 		$139K Buy
19,899
+1,161
+6% +$10.6K ﹤0.01% 3960
2024
Q4 		$275K Buy
18,738
+4,573
+32% +$72.4K ﹤0.01% 3824
2024
Q3 		$271K Sell
14,165
-6,067
-30% -$116K ﹤0.01% 3816
2024
Q2 		$356K Buy
+20,232
New +$326K ﹤0.01% 3739

Other funds holding CTNM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's CTNM Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 65,604 shares worth $1.08M. The stake represents ﹤0.01% of the portfolio and ranks #3316 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in CTNM as recently as Q1 2025.

Bank of New York Mellon first reported a position in CTNM in Q2 2024 and has held it in 5 quarters since. 23 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Bank of New York Mellon held 65,604 shares of Contineum Therapeutics worth $1.08M as of Q2 2026.
  • Contineum Therapeutics was a new Bank of New York Mellon position in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3316 holding.
  • Bank of New York Mellon first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 23 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.